alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 776–800 of 2,047 studies published 2026 (page 32 of 82) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Cholinesterase inhibitors for patients with dementia: Patterns of prescribing and disparities in treatment

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of Alzheimer s Disease 2026-01-13

BackgroundCholinesterase inhibitors (ChEIs) are cornerstones of the symptomatic treatment of Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) and are also prescribed for vascular dementia (VaD). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The role of verbal episodic memory in progression to mild cognitive impairment: The influence of serial position effects

✓ Peer-reviewed alzhub usefulness score 40 out of 100. International Psychogeriatrics 2026-04-01

SCD participants were older, had fewer years of education, more depressive symptoms, and more subjective cognitive complaints than CU participants. 4 key findings →

Participants: 315 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Rationale and design of a multidomain lifestyle program for mild cognitive impairment

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Alzheimer s & Dementia 2026-01-01

The development of non-pharmacological treatment approaches is supported by evidence that addressing key modifiable risk factors may prevent or delay up to 45% of dementia cases. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

CD33 and clusterin interact biophysically and genetically to modulate Alzheimer risk

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Nature Communications 2026-07-17

We report the results of structural, functional and genetic studies on the CD33 sialic acid- binding receptor that reveal how non-coding variants in CD33 alter risk for Alzheimer’s disease (AD). 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Psychometric properties, pragmatic screening cut‐offs, and feasibility of two Clock Drawing Test formats in older psychiatric outpatients: Associations with MMSE and HDS‐R

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Psychiatry and Clinical Neurosciences Reports 2026-05-25

Both CDT formats showed clinically useful psychometric properties and similar pragmatic cut‐offs in older psychiatric outpatients. 1 key finding →

Participants: 20 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Electrical stimulation of the vagus nerve improves amyloid pathology in delirium superimposed on dementia

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Bioelectronic Medicine 2026-01-16

In AD-like mice surgery induced acute changes in amyloid-β; perioperative treatment with pVNS effectively reduced amyloid-β load, plaque sphericity, and neuronal loss. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Scalable human neuronal models of tauopathy producing endogenous seed-competent 4R tau

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Science Advances 2026-07-31

The accumulation of pathological four-repeat (4R) tau is central to several frontotemporal dementia (FTD) subtypes, but human neuronal models amenable to high-throughput screening of 4R tau-targeting therapies remain very limited. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

MAPT splicing modulators reduce 4R tau and rescue tauopathy phenotypes in human neurons and in a mouse model

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Science Translational Medicine 2026-08-19

Tauopathies are neurodegenerative diseases characterized by the pathological accumulation of microtubule-associated protein tau (MAPT) in the brain. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Ultra‐processed food intake, cognitive function, and dementia risk: A cross‐sectional study of middle‐aged and older Australian adults

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring 2026-04-01

Each 10% increase in UPF intake was associated with lower attention scores (-0.05 points) and higher dementia risk (+0.24 points), independent of Mediterranean diet adherence. 2 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Delirium: an urgent health priority in Australian hospitals

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Public Health Research & Practice 2026-05-26

Delirium is a common health problem with serious and long-lasting health consequences that disproportionately affects vulnerable population groups (especially older people with dementia or frailty). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Guiding the Ethics of Locator Devices in Dementia Care: Tutorial on Developing a Question-Based Ethical Framework

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of Medical Internet Research 2026-07-07

The resulting framework is organized around 3 themes-vision, process, and impact-each containing guiding questions that encourage dialogical reflection and decision-making. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The End of Life With Dementia in Asian Countries: Barriers, Facilitators and a Research Agenda for Advancing a Palliative Approach

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of the American Geriatrics Society 2026-01-13

Broad barriers identified in the outer setting of the implementation framework include sociocultural values and a lack of supportive policies, guidelines, and financing. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Artificial Intelligence That Changes Clinical Neurology Practice: Translating Algorithms Into Actionable Care

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of clinical neurology (Seoul, Korea) 2026-07-09

Artificial intelligence (AI) has stimulated extensive research in clinical neurology, but relatively few AI systems have meaningfully changed bedside decision-making. 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source

Long-term effect of discontinuing anticholinesterase treatment on cognitive decline and mortality in Alzheimer's disease in France: a quasi-experiment and target trial emulation study

✓ Peer-reviewed alzhub usefulness score 40 out of 100. The Lancet regional health. Europe 2026-02-24

In 2018, France withdrew reimbursement for cholinesterase inhibitors (ChEIs) in Alzheimer's disease, citing modest efficacy, lack of long-term benefit, and safety concerns. 3 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed